Daclizumab Biosimilar – Anti-IL2RA mAb – Research Grade

Description of Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade

General information on Anti-IL2RA(Homo sapiens) (Daclizumab) Monoclonal Antibody

Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.

Daclizumab Biosimilar - Anti-IL2RA mAb binds to Human CD25/IL2RA in indirect ELISA Assay

Immobilized Interleukin-2 receptor subunit alpha(IL2RA) (cat. No. PX-P4704) at 0.5µg/mL (100µL/well) can bind Daclizumab Biosimilar - Anti-IL2RA mAb (cat. No. PX-TA1038) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 175.8M.

SDS-PAGE for Daclizumab Biosimilar - Anti-IL2RA mAb

Daclizumab Biosimilar - Anti-IL2RA mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.